Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 3
2009 1
2010 1
2011 8
2012 9
2013 10
2014 27
2015 63
2016 46
2017 106
2018 128
2019 225
2020 305
2021 500
2022 584
2023 635
2024 210

Text availability

Article attribute

Article type

Publication date

Search Results

2,558 results

Results by year

Filters applied: . Clear all
Page 1
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Kudo M, et al. Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1. Lancet. 2018. PMID: 29433850 Free article. Clinical Trial.
INTERPRETATION: Lenvatinib was non-inferior to sorafenib in overall survival in untreated advanced hepatocellular carcinoma. The safety and tolerability profiles of lenvatinib were consistent with those previously observed. FUNDING: Eisai Inc....
INTERPRETATION: Lenvatinib was non-inferior to sorafenib in overall survival in untreated advanced hepatocellular carcinoma. The safe …
N6-Methyladenosine-Mediated Up-Regulation of FZD10 Regulates Liver Cancer Stem Cells' Properties and Lenvatinib Resistance Through WNT/beta-Catenin and Hippo Signaling Pathways.
Wang J, Yu H, Dong W, Zhang C, Hu M, Ma W, Jiang X, Li H, Yang P, Xiang D. Wang J, et al. Gastroenterology. 2023 May;164(6):990-1005. doi: 10.1053/j.gastro.2023.01.041. Epub 2023 Feb 8. Gastroenterology. 2023. PMID: 36764493 Free article.
Importantly, the FZD10/beta-catenin/c-Jun/MEK/ERK axis determines the responses of hepatoma cells to lenvatinib treatment. Analysis of patient cohort, patient-derived tumor organoids, and patient-derived xenografts further suggest that FZD10 might predict lenvatinib …
Importantly, the FZD10/beta-catenin/c-Jun/MEK/ERK axis determines the responses of hepatoma cells to lenvatinib treatment. Analysis o …
Resistance of Lenvatinib in Hepatocellular Carcinoma.
Guo J, Zhao J, Xu Q, Huang D. Guo J, et al. Curr Cancer Drug Targets. 2022;22(11):865-878. doi: 10.2174/1568009622666220428111327. Curr Cancer Drug Targets. 2022. PMID: 36267045 Review.
Lenvatinib is a multikinase inhibitor which mainly hinders liver cancer proliferation by inhibiting angiogenesis. ...Accordingly, it is necessary to determine factors associated with Lenvatinib resistance and explore solutions. In this review, we sought to explore t …
Lenvatinib is a multikinase inhibitor which mainly hinders liver cancer proliferation by inhibiting angiogenesis. ...Accordingly, it …
METTL1-Mediated m7G tRNA Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma.
Huang M, Long J, Yao Z, Zhao Y, Zhao Y, Liao J, Lei K, Xiao H, Dai Z, Peng S, Lin S, Xu L, Kuang M. Huang M, et al. Cancer Res. 2023 Jan 4;83(1):89-102. doi: 10.1158/0008-5472.CAN-22-0963. Cancer Res. 2023. PMID: 36102722
The tyrosine kinase inhibitor lenvatinib is a first-line drug for treating patients with advanced hepatocellular carcinoma (HCC). ...METTL1 knockdown overrode resistance by impairing the proliferation capacity of HCC cells and promoting apoptosis under lenvatinib tr …
The tyrosine kinase inhibitor lenvatinib is a first-line drug for treating patients with advanced hepatocellular carcinoma (HCC). ... …
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients.
Persano M, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Yoo C, Lonardi S, Tovoli F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Niizeki T, Montes M, Vivaldi C, Soldà C, Stefanini B, Hiraoka A, Sho T, Nishida N, Steup C, Iavarone M, Di Costanzo G, Marra F, Tamburini E, Cabibbo G, Foschi FG, Silletta M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Campani C, Amadeo E, Rossari F, Burgio V, Cascinu S, Scartozzi M, Casadei-Gardini A. Persano M, et al. Eur J Cancer. 2023 Aug;189:112933. doi: 10.1016/j.ejca.2023.05.021. Epub 2023 Jun 1. Eur J Cancer. 2023. PMID: 37385069 Free article.
CONCLUSION: Approximately half of patients receiving first-line lenvatinib or atezolizumab plus bevacizumab access second-line treatment. Our data suggest that in patients progressed to atezolizumab plus bevacizumab, the systemic therapy able to achieve the longest surviva …
CONCLUSION: Approximately half of patients receiving first-line lenvatinib or atezolizumab plus bevacizumab access second-line treatm …
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI. Schlumberger M, et al. N Engl J Med. 2015 Feb 12;372(7):621-30. doi: 10.1056/NEJMoa1406470. N Engl J Med. 2015. PMID: 25671254 Free article. Clinical Trial.
A progression-free survival benefit associated with lenvatinib was observed in all prespecified subgroups. The response rate was 64.8% in the lenvatinib group (4 complete responses and 165 partial responses) and 1.5% in the placebo group (P<0.001). ...Discontinua …
A progression-free survival benefit associated with lenvatinib was observed in all prespecified subgroups. The response rate was 64.8 …
Lenvatinib: A Review in Hepatocellular Carcinoma.
Al-Salama ZT, Syed YY, Scott LJ. Al-Salama ZT, et al. Drugs. 2019 Apr;79(6):665-674. doi: 10.1007/s40265-019-01116-x. Drugs. 2019. PMID: 30993651 Review.
In REFLECT, lenvatinib was non-inferior, but not superior, to sorafenib (current standard of care) for overall survival (OS). ...Further clinical experience may be required to fully define the position of lenvatinib in this setting....
In REFLECT, lenvatinib was non-inferior, but not superior, to sorafenib (current standard of care) for overall survival (OS). ...Furt …
Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies.
Motzer RJ, Taylor MH, Evans TRJ, Okusaka T, Glen H, Lubiniecki GM, Dutcus C, Smith AD, Okpara CE, Hussein Z, Hayato S, Tamai T, Makker V. Motzer RJ, et al. Expert Rev Anticancer Ther. 2022 Apr;22(4):383-400. doi: 10.1080/14737140.2022.2039123. Epub 2022 Apr 7. Expert Rev Anticancer Ther. 2022. PMID: 35260027 Free PMC article. Review.
INTRODUCTION: Lenvatinib is an oral multitargeted tyrosine kinase inhibitor that has shown efficacy and manageable safety across multiple cancer types. ...The dosing and adverse-event management strategies for lenvatinib have been developed through extensive clinica …
INTRODUCTION: Lenvatinib is an oral multitargeted tyrosine kinase inhibitor that has shown efficacy and manageable safety across mult …
METTL3-m(6)A-EGFR-axis drives lenvatinib resistance in hepatocellular carcinoma.
Wang L, Yang Q, Zhou Q, Fang F, Lei K, Liu Z, Zheng G, Zhu L, Huo J, Li X, Peng S, Kuang M, Lin S, Huang M, Xu L. Wang L, et al. Cancer Lett. 2023 Apr 10;559:216122. doi: 10.1016/j.canlet.2023.216122. Epub 2023 Mar 9. Cancer Lett. 2023. PMID: 36898427
Here, we aimed to investigate the modulatory effects and underlying mechanisms of m(6)A in lenvatinib resistance in HCC. Our data revealed that m(6)A mRNA modification was significantly upregulated in the HCC lenvatinib resistance (HCC-LR) cells compared to parental …
Here, we aimed to investigate the modulatory effects and underlying mechanisms of m(6)A in lenvatinib resistance in HCC. Our data rev …
Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy.
Zhao Y, Zhang YN, Wang KT, Chen L. Zhao Y, et al. Biochim Biophys Acta Rev Cancer. 2020 Aug;1874(1):188391. doi: 10.1016/j.bbcan.2020.188391. Epub 2020 Jul 10. Biochim Biophys Acta Rev Cancer. 2020. PMID: 32659252 Free article. Review.
Lenvatinib, a multi-target tyrosine kinase inhibitor (TKI), is an emerging first-line therapy for hepatocellular carcinoma (HCC). ...Positive outcomes have been achieved in the combination of lenvatinib plus ICIs, bringing broader prospects for HCC. This review pres …
Lenvatinib, a multi-target tyrosine kinase inhibitor (TKI), is an emerging first-line therapy for hepatocellular carcinoma (HCC). ... …
2,558 results